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Abstract—Chronic Lymphocytic Leukemia (CLL) is the
most common peripheral blood and bone marrow can-
cer in the developed world. This manuscript proposes
mathematical model equations representing the disease
dynamics of B-cell CLL. We interconnect delay differential
cell cycle models in each of the tumor-involved disease
centers using physiologically-relevant cell migration. We
further introduce 5 hypothetical case studies representing
CLL heterogeneity commonly seen in clinical practice
and demonstrate how the proposed CLL model frame-
work may capture disease pathophysiology across patient
types. We conclude by exploring the capacity of the
proposed temporally- and spatially-distributed model to
capture the heterogeneity of CLL disease progression. By
using Global Sensitivity Analysis, the critical parameters
influencing disease trajectory over space and time are:
(i) the initial number of CLL cells in peripheral blood,
the number of involved lymph nodes, the presence and
degree of splenomegaly; (ii) the migratory fraction of non-
proliferating as well as proliferating CLL cells from bone
marrow into blood and of proliferating CLL cells from
blood into lymph nodes; (iii) the parameters inducing non-
proliferative cells to proliferate. The proposed model offers
a practical platform which may be explored in future
personalized patient protocols once validated.
1. INTRODUCTION
Chronic Lymphocytic Leukemia (CLL) is the most
common peripheral blood and bone marrow cancer in the
developed world, usually afflicting older individuals [1].
It is a heterogeneous disease consisting of abnormal pro-
liferation and reduced apoptosis in mutated clones, most
commonly of mature B-cells, resulting in accumulation
in 4 compartments: the bone marrow, peripheral blood,
lymph nodes and spleen. Initial chromosomal mutations
differ between patients and malignant transformations
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progress variably. Subclonal mutations may arise and
overtake the dominant clone because of other stressors,
such as chemotherapy used to treat the original disease
[2]. The site of primary CLL pathogenesis is the lymph
nodes and/or bone marrow with cells then circulating in
peripheral blood and homing preferentially towards bone
marrow, lymph nodes, or spleen depending on expression
of chemokine receptors or intracellular proteins [3]–[5];
this heterogeneity results in variable presentations of
lymphocytosis, bone marrow failure, lymphadenopathy
and splenomegaly [6, 7] with the clinical stages of
disease defined using the Binet [8] or Rai [9] systems and
WHO [10] criteria for diagnosis (Table 1). The disease
typically progresses slowly with most CLL cells arrested
in the resting (G0) or growth (G1) phases of the cell
cycle [11]. Since CLL has defined mutations predictive
of prognosis and a chronic trajectory often spanning
decades, we hypothesize that mathematical models may
characterize CLL disease dynamics with the potential to
act as a framework for personalized treatment strategies.
Diverging from previous mathematical models for B-
cell CLL (hereafter referred to as CLL), this manuscript
presents the first personalized, physiologically-relevant
mathematical framework modeling CLL with features
that (1) consider each of the most relevant disease centers
including those of bone marrow, peripheral blood, lymph
nodes and spleen, (2) interconnect the affected tissues
via descriptors for cell migration, (3) calculate migration
rates between affected tissues and (4) provide a frame-
work to predict CLL progression over the disease course,
in the absence of treatment. This work belongs to an
ongoing effort developing building blocks for modeling
and optimizing biomedical systems [12] such as that
for Acute Myeloid Leukemia [13, 14], Type 1 Diabetes
Mellitus [15] and for the delivery of anesthesia [16, 17].
We previously performed a more limited global sensi-
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TABLE 1: Clinical Staging and Corresponding PB Lym-
phocyte Doubling Time (LDT) [8]–[10, 19, 20]
Symptoms CLL Clinical Stage LDT [months± SEM]
Rai Binet
Lymphocytosis




A (< 3 areas of




and splenomegaly) 10.8± 2.1
Anemia (Hgb < 11 g/dL) III
C 10.8± 4.4
Lymphocytosis and IV
thrombocytopenia (PLT < 1011 /L)
WHO classification: Lymphocytosis ≥ 5× 109 cells/L for ≥ 3 mon with:
Immunophenotype: SIG, CIG−/+, CD5, CD23, CD43, CD19, CD20, CD79a;
Genetics: IgVH, trisomy 12, [del(13q14.1)], [del(11q)], [del(6q)], [del(17p)]
SEM ≡ Standard Error Mean
TABLE 2: Expected lymphocyte count† [21, 22]





Blood (PB) 10× 109 2.2% 25 70 5
Lymph nodes (LN) 190× 109 41.3% 20 70 10
Spleen (S) 70× 109 15.2% 50 40 10
Gut Lymphoid Tissue 20× 109 4.3%
Thymus 50× 109 10.9% < 1 > 95
Bone Marrow (BM) 50× 109 10.9% 50 50
Other tissue 70× 109 15.2%
† Assuming a 70 kg human with 460× 109 total lymphocytes
Fig. 1: CLL modeling framework incorporates the major
disease compartments
tivity analysis than that described in Online Supplement
Appendix F [18]; otherwise the manscript has all new
material.
2. MATHEMATICAL MODEL
The model (Fig. 1) consists of 3 cell cycle models and
the interconnectivity between them; we assume that CLL
cells are distributed in bone marrow (BM), peripheral
Fig. 2: Normalized feedback function (Eq 2) in semi-
logarithmic plot (n = 3) [23]
blood (PB), and lymph nodes (LN) and spleen (S) at the
point of diagnosis and that S is aggregated with LN.
A. Chronic Lymphocytic Leukemia (CLL)
Our model (Fig. 1) is a general framework which
captures the following dynamics: as CLL cells proliferate
in BM (as captured at diagnosis – the pre-diagnosis
disease-initiating mutation(s) may occur in either LN or
S and then populate BM), the cells may either migrate to
PB and then LN or stay in BM. It includes 3 cell cycles
and migration rates for both proliferative (P ) and non-
proliferative (N ) CLL cells from BM to PB (BM2PB)
and then to LN (PB2LN); this model applies to naïve
stage and Binet stages A – C (SN, SA, SB, SC). Eqs (1)
– (12) represent the specific case where: (a) the Mackey
[23] G0 model (Appendix A) is correct and (b) we have
data regarding lymphocyte counts and proliferation in
affected tissues (Tables 1 & 2). While we limit our
analysis to a proliferating/non-proliferating model [23],
an equivalent development could be constructed for a
detailed G1→ S→ G2/M cell cycle model, e.g., [24].
Before defining the 3 interconnected G0 models in Eqs
(7) – (12), we define a time delay (Eq 1), proliferation
feedback function (Eq 2 & 3), and the relationship
between Ki-67 expression, i.e., percent proliferation, and
cell numbers for each disease center i ∈ {BM, PB, LN}
and disease stage z ∈ {SN, SA, SB, SC}.
Ni,τi, z = Ni(t− τi, z) (1)
βi(Ni) = βNi, 0 · θnii / (θnii +Nnii ) (2)
θi = θi, 1, z (t− tin, z) + θi, 2, z (3)
Ki-67i = Pi / (Pi +Ni) (4)
In the Eq (2) feedback function, βNi, 0 is the maximum
recruitment in each tissue [25]. Fig. 2 illustrates Eq (2)
for n = 3 and demonstrates that control parameter θi
modulates recruitment from non-proliferative (Ni) and
proliferative (Pi) phases. The θi value is larger in CLL
proliferation centers, i.e., BM, LN and S, than in the
accumulation compartment (PB) where the expression
of proliferative marker Ki-67 is lowest [26].
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The BM disease center has restricted volume
(BMmax ≈ 13.5 × 1011 lymphocytes; Appendix B).
Assuming that the normal lymphocyte count in BM
remains constant, carrying capacity, cc, represents re-
stricted volume [27], aBM is the percentage of normal
lymphocytes in BM (see Appendix B), and CNC,BM is
the number of lymphocytes in normal BM (Table 2):
%BMlymph =
CNC,BM +NBM + PBM
1
aBM
CNC,BM + PBM +NBM
(5)
cc(NBM, PBM) = 1− CNC,BM +NBM + PBMBMmax (6)
BM Eqs (7 – 8) hold ∀ z ∈ {SN, SA, SB, SC}:
dNBM
dt
=− δBM, z NBM
− βBM(NBM) NBM cc(NBM, PBM)
+ 2 βBM(NBM, τBM, z ) NBM, τBM, z
e−γBM, z τBM, z cc(NBM, PBM)




=− γBM, z PBM
+ βBM(NBM) NBM cc(NBM, PBM)
− βBM(NBM, τBM, z ) NBM, τBM, z
e−γBM, z τBM, z cc(NBM, PBM)
− kP,BM2PB, z PBM
(8)
PB Eqs (9) & (10) hold ∀ z ∈ {SN, SA, SB, SC}:
dNPB
dt
=− δPB, z NPB − βPB(NPB) NPB
+ 2 βPB(NPB, τPB, z ) NPB, τPB, z
e−γPB, z τPB, z




=− γPB, z PPB + βPB(NPB) NPB
− βPB(NPB, τPB, z ) NPB, τPB, z
e−γPB, z τPB, z
+ kP,BM2PB, z PBM − kP, PB2LN, z PPB
(10)
LN Eqs (11) & (12) hold ∀ z ∈ {SN, SA, SB, SC}:
dNLN
dt
=− δLN, z NLN − βLN(NLN) NLN
+ 2 βLN(NLN, τLN, z ) NLN, τLN




=− γLN, z PLN + βLN(NLN) NLN
− βLN(NLN, τLN, z ) NLN, τLN, z
e−γLN, z τLN, z + kP, PB2LN, z PPB
(12)
B. Algorithm for Determining Cell Cycle Parameters
The model is an index-1 system with 6 differential
and 23 algebraic equations, 76 parameters (22 assumed,
TABLE 3: Data sources for determining input parameters
Parameter Experimental Method Source
Experiments in Common Clinical Practice
dLN, CLL Ultrasound; CT scan [7]
dS, CLL CT scan [7]
lS, CLL CT scan [7]
VCLL, LN Ultrasound Est.
VCLL, S CT scan or from enlarged dimensions [7]
NuLN, dLN, CLL CT scan [7]
Ki-67 Flow cytometry [26]
%BM Bone marrow biopsy [28]
Other Possible Experiments
τ Response to PHA [29]
δ, γ In vivo: Labelled 2H2O; Ex vivo: Trypan




NBM, PBM %Ki-67BM and %BM in Eq 5
NPB, PPB %Ki-67PB and blood tests
NLN, PLN %Ki-67LN and LN / S measurements by CT scan
38 calculated, 10 measured, 6 initial conditions), 6 state
variables and 33 variables. Table 7 defines the symbols.
Table 1 outlines PB lymphocyte doubling time (LDT)
and clinical staging [19]. The 3 parameter types are:
(a) Assumed parameters from average human physiol-
ogy or mathematical analysis – these parameters
would be typically clinically unavailable,
(b) Measured parameters may be directly determined –
Table 3 proposes experimental methods and Table 7
lists typical values. Note that some measurements,
e.g., from PB, may be taken more frequently than
from others, such as BM or LN,
(c) Calculated parameters that are deduced indirectly –
this section proposes a relevant algorithm.
Fig. 3 is an example of patient data trajectory within
a disease stage. Transition time, or CLL stage duration
∆tz = tfin, z − tin, z , is estimated by treating physicians
based on changes in PB LDT, increased lymphadenopa-
thy or splenomegaly and low levels of hemoglobin or
platelets. Appendices D – E describe an algorithm we
developed in GAMS and MATLAB which finds values
of θi, 1, z , θi, 2, z , δi, z, γi, z and kN,BM2PB, z , kP,BM2PB, z ,
kN, PB2LN, z , kP, PB2LN, z , ∀ i ∈ {BM, PB, LN} and ∀ z ∈
{SN, SA, SB, SC}; this algorithm takes the measurable
parameters and deduces reasonable values for the calcu-
lated parameters. We seek reasonable parameters rather
than guaranteed parameter estimates of the best possible
values; our purpose is to capture disease dynamics. We
define reasonable parameters as satisfying the Table 1
disease characteristics and the Table 7 Source column;
further model building could augment these restrictions.
C. Global Sensitivity Analysis
We apply random sampling - high dimensional model
representation (RS-HDMR; Appendix F) global sensitiv-
ity analysis [35, 36] to the nominal parameter values. The
minimum and maximum values of parameters included
in Table 4 are used as inputs to the RS-HDMR model
analysis (Table F.1 in Appendix F). The RS-HDMR
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TABLE 4: Cell cycle calculated and assumed parameters for the 5 hypothetical patients (P1 – P5)
P1 P2 P3 P4 P5
Initial Final Initial Final Initial Final Initial Final Initial Final




† 1/day 0.774 0.774 0.823 0.091 0.780 0.720 0.252 0.810 0.655 0.094
γLN
† 1/day 0.861 0.861 0.861 0.860 0.841 0.866 0.586 0.629 0.530 0.847
γPB 1/day 0.001 0.001 0.001 0.003 0.001 0.006 0.001 0.001 0.001 0.006
δBM 1/day 0.001 0.001 0.001 0.034 0.001 0.001 0.001 0.001 0.001 0.037
δLN
† 1/day 0.001 0.001 0.001 0.001 0.001 0.001 0.020 0.020 0.020 0.001
δPB 1/day 0.001 0.001 0.001 0.003 0.001 0.001 0.001 0.001 0.001 0.001
τBM day 0.792 0.792 0.792 0.625 0.792
τLN day 0.792 0.792 0.792 0.792 0.792
τPB day 0.792 0.625 0.625 0.625 0.625
θBM, 1
† ·108 cells 0.008 0.029 0.057 0.481 0.278 0.693 0.558 3.145 0.004 6.209
θBM, 2 ·108 cells 91.987 100.082 173.649 258.275 172.191 273.513 280.398 485.678 80.412 117.593
θLN, 1
† ·108 cells 0.265 0.372 0.154 0.451 1.134 1.223 10.811 19.297 1.120 5.160
θLN, 2 ·108 cells 0.001 265.039 329.114 607.436 327.621 745.614 303.030 4788.246 281.928 714.329
θPB, 1 ·108 cells 0.001 0.008 0.007 0.104 0.063 0.132 0.677 1.259 0.018 0.224
θPB, 2 ·108 cells 15.000 16.450 20.000 33.050 20.000 43.100 210.000 457.000 45.000 51.450
kN,BM2PB
† 1/day 0.003 0.003 0.001 0.004 0.002 0.005 0.035 0.011 0.005 0.001
kP,BM2PB
† 1/day 0.003 0.001 0.001 0.001 0.001 0.001 0.003 0.001 0.001 0.001
kN, PB2LN
† 1/day 0.003 0.002 0.001 0.001 0.001 0.003 0.005 0.001 0.001 0.001
kP, PB2LN
† 1/day 0.033 0.007 0.013 0.007 0.008 0.006 0.001 0.001 0.001 0.014
Assumed
Parameters
tin day 0 1000 0 1800 0 365 0 365 0 365
tfin day 1000 3190 1800 2165 365 730 365 730 365 730
† Critical parameters along with the patients initial conditions in RS-HDMR analysis (Appendix F, Figure F.2)
TABLE 5: Initial characteristics of the 5 hypothetical patients (more details in Appendix Table E.1)
Patient P1 P2 P3 P4 P5 CLL
Bone Marrow Infiltration 37.3% 46.7% 46.7% 52.1% 37.4%
CLL in PB (cells/µL) 6018 8016 8016 84168 18040 ≥ 5000 for at
least 3 months†
[10]
LN & S (cells) 0 1340 · 108 1340 · 108 1326 · 108 1047 · 108
Ki-67 % in PB 0.30% 0.20% 0.20% 0.20% 0.22% 0.36 ± 0.34 % ‡ [26]
LN & S 0.00% 2.99% 2.99% 2.00% 4.50% 4.95 ± 0.55 % ‡ [26]
4.50 ± 2.50 % ‡ [34]
BM 2.70% 1.95% 1.95% 3.00% 1.76% 2.48 ± 0.77 % ‡ [26]
Expected LDT (months) ∞→ 60 60→ 12 12→ 12 12→< 12 60→< 12 [19]
†Values for CLL published by the World Health Organization, ‡Average values of Ki-67 in tissues
output variables are the number of proliferative and non-
proliferative CLL cells in BM, PB and LN including S.
3. CASE STUDIES
The initial characteristics of 5 hypothetical patients
(P1 – P5) are posited in Table 5. The 5 hypothetical
patients represent a range of clinically-relevant phys-
iological conditions (disease heterogeneity) based on
common disease presentation (Table 1 and Appendices
C – G). The only exception is P3 which represents the
model outcome described by Molica et al. [37] where a
patient in Binet Stage A has a lymphocyte doubling time,
LDT ≤ 12 months (Appendix E). The 5 hypothetical
patient trajectories (P1 – P5) we model are:
• P1: Naïve Stage (LDT: ∞) →
Binet Stage A (LDT= 60 months)
• P2: Binet Stage A (LDT = 60 months) →
Binet Stage B (LDT = 12 months)
• P3: Binet Stage A (LDT = 12 months) →
Binet Stage B (LDT = 12 months)
• P4: Binet Stage B (LDT = 12 months) →
Binet Stage C (LDT = 12 months)
• P5: Binet Stage A (LDT = 60 months) →
Binet Stage C (LDT = 7 months)
We also make the following assumptions: (a) normal
lymphocyte count in each tissue is stable, (b) zero
net migration of normal lymphocytes, (c) normal bone
marrow lymphocytes have percentage aBM = 25% [38],
(d) peripheral blood volume is 5 L [39], (e) the maximum
recruitment rate βN, 0 equals 3.35 /day in each tissue
[25]; (f) CLL disease stage duration, ∆tz , is based on
LDT (Table 1) and has values [days]: 1000, 1800, 365,
365 and 365 for the 5 case studies, P1 – P5, respectively.
We apply the Section 2.B algorithm for determin-
ing parameters to the 5 case studies, simulate the tra-
jectories of Eq (1) – (12) and predict future patient
signs/sequelae via correlation with the simulated CLL
cells number in each disease center. For more detail,
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Fig. 3: Example patient trajectory within a disease stage;
horizontal lines show PB LDT calculation and vertical
lines show transition from initial diagnosis at time tin to
the point of progression to a new phase at tfin
see Appendix D. We consider 4 types of physical signs:
(a) high infiltration pattern of BM predicted from Eq
(5), (b) only splenomegaly, (c) only lymphadenopathy,
and (d) combined splenomegaly and lymphadenopathy
(Appendices C and G). We implemented the model
in MATLAB R2013a (8.1.0.604) and GAMS 24.1.3
(solver: CONOPT) on a 4.40 GHz Intel Core i7-4770
processor with 8GB RAM running 64-bit Windows 7;
each simulation took 0.1 – 0.2 CPU s.
4. RESULTS AND DISCUSSION
Results are in Tables 4 & 6 and Fig. 4. The clinical
predictions in Table 6 are based on analyses in Appen-
dices C and G; Fig. 4 diagrams the MATLAB outputs.
The sequel comments on each of the 5 case studies.
P1 starts from a naïve stage with high LDT and
progresses to Binet Stage A (LDT 60 months); the pro-
liferation increase of ≈ 33 months after initial diagnosis
correlates with the increased recruitment rates into the
bonemarrow and lymph node cell cycles. P2 and P3
have similar initial disease characteristics (% CLL cells
in bone marrow and %Ki-67) but diverge with respect
to initial LDT; these two test cases correspond to work
showing that LDT significantly impacts the probability
of progression from Binet Stage A to B within a year
[37]. The model captures this progression tempo; P2 and
P3 progress to Stage B in 60 and 12 months, respectively.
P4 shows a trajectory from Binet Stage B to C where
the bone marrow pattern changes from mixed to diffuse
and the rate of lymphocyte doubling is roughly constant
at 12 months; the fraction of CLL cells migrating de-
creased or remained stable in the P4 trajectory. Note here
that, although the definition of Binet Stage C requires
a descriptor of anemia and low platelets (Table 1), we
use instead an indirect metric, assuming that the signs
of Binet Stage C will follow from an increase in bone
marrow tumor burden. Finally, P5 is an unusual CLL
case; the disease initiates slowly in Binet Stage A and
bone marrow failure occurs quickly within 2 years.
RS-HDMR analysis of the CLL model in Binet Stages
from A to C, illustrated in Fig. F.2 of Appendix F for
5000 HDMR samples is done in Matlab with dde23
solver. The parameters (Si ≥ 0.1) of this model which
most significantly affect disease trajectory over space and
time are: (i) the initial number of CLL cells in peripheral
blood, the number of involved (enlarged) lymph nodes
and the presence and degree of splenomegaly, (ii) the
migratory fractions of non-proliferating as well as pro-
liferating CLL cells from bone marrow into peripheral
blood and of proliferating CLL cells from peripheral
blood to lymph nodes and, (iii) the parameter induc-
ing non-proliferative cells to proliferate. Several critical
parameters identified by our model (enlarged lymph
nodes, splenomegaly, LDT) are already used in staging
systems, but none of: (i) total CLL cell number, (ii)
migration rate and, (iii) propensity to induce proliferation
(unless directly incurred by a known mutation, e.g., p53,
or mutated pathway) is currently used. We therefore
propose these factors for inclusion in multi-parameter
models of disease progression, as targets for prevention
of progression or therapy. In particular, the use of
migration rate, e.g., using chemokine or integrin surface
markers or other relevant serum biomarkers, and the
induction of a cell proliferation profile, e.g., via mutated
cell cycle checkpoints or intracellular pathways such as
PI3K, could be important focal points for inclusion in
future research. These parameters could be made readily
available for input into models on a patient-specific basis
over the disease course from peripheral blood tests done
at the bedside (for migration assessments) and from
sampling of the primary disease center, e.g., lymph node
or bone marrow for proliferation parameters via fine
needle aspirate or core biopsy - both routine procedures.
Expression of Ki-67, a proliferation marker found in
cycle phases G1, S, G2, and M but not G0 [40], is found
in tissues affected by CLL in varying percentage: periph-
eral blood 0.36±0.34%, bone marrow 2.48±0.77%, and
lymph nodes and spleen 4.95± 0.55% [26]. In addition
to having higher proliferative features than those of bone
marrow or peripheral blood, lymph nodes and spleen dis-
ease centers in CLL also have lower death rates [33, 34],
a feature which has been partially attributed to the
microenvironment [41]. One of the earliest mathematical
frameworks of CLL models the interaction between CLL
cells and T-cells, a component of the microenvironment,
via a Volterra predator-prey equation [42]. A kinetic
model [30] has also been used to develop the first model
of CLL incorporating interactions between CLL cells,
natural killer (NK) cells, cytotoxic (CD8+) T-cells and
helper (CD4+) T-cells [43]. This model implicitly as-
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(a) Lymphocytes in organs (b) Bone marrow infiltration pattern (c) Ki-67 in organs
Fig. 4: Characteristics of CLL in theoretical patients P1 – P5. Each row represents one patient; the vertical dashed
lines represent transitions between disease stages
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TABLE 6: Possible characteristics of 5 hypothetical patients derived from the mathematical model
Symptoms Initially Finally
P1: Naïve → Binet Stage A
Bone marrow pattern Interstitial or nodular Interstitial or nodular
Enlarged lymph nodes No [Diameter (cm), #] [3, 5], [4, 2], [5, 1]
LDT: ∞→ 60 months Splenomegaly No No
P2: Binet Stage A → B
Bone marrow pattern Interstitial or nodular Mixed
Enlarged lymph nodes Yes [Diameter (cm), #] [3, 2], [4, 1]
LDT: 60 months → 12 months Splenomegaly No Mild to moderate (5× 12 cm)
P3: Binet Stage A → B
Bone marrow pattern Interstitial or nodular Mixed
Enlarged lymph nodes Yes [Diameter (cm), #] [3, 4], [4, 2]
LDT: 12 months → 12 months Splenomegaly No Mild to moderate (5× 12 cm)
P4: Binet Stage B → C
Bone marrow pattern Mixed Diffuse
Enlarged lymph nodes Yes [Diameter (cm), #] [4, 11], [5, 6], [6, 5]
LDT: 12 months → 12 months Splenomegaly No Marked (7× 14 cm)
P5: Binet Stage A → C
Bone marrow pattern Interstitial or Nodular Diffuse
Enlarged lymph nodes No [Diameter (cm), #] [3, 5], [4, 2]
LDT: 60 months → 7 months Splenomegaly No Mild to moderate (5× 15 cm)
sumes that the entire body is 1-compartment and thereby
does not account for the proliferation center microenvi-
ronment, disease center carrying capacity, or the cellular
migration between disease centers [43]. CLL lymphocy-
tosis kinetics have been studied using a 2-compartment
model [30] that characterizes CLL cell redistribution
dynamics from proliferation centers into the peripheral
blood induced by the novel BTK inhibitor, Ibrutinib
albeit there is little known about steady-state dynamics
or of that which occurs during the natural course of
disease [44]. Variations may assume different cell cycle
models for each disease compartment. For example,
immunophenotyping to distinguish between B- and T-
cells in the peripheral blood lymphocyte compartment
[41, 45] which may facilitate the incorporation of im-
mune interactions and current immuno-chemotherapeutic
targets [46]. Our model therefore complements the 1-
compartment model of Nanda et al. [43]. If we could
assume data on T-cell populations, i.e., CD4+, CD8+, the
Nanda et al. [43] model could replace each G0 model in
Fig. 1. This manuscript does not use the optional T-cell
module and reflects data availability from typical clinical
protocols with first-order approximation that 90% of
lymphocytes in affected tissues are CLL cells [41].
Our model meaningfully adapts to each of the dis-
parate case studies and the parameters and variables
adhere to physiologically-relevant values. The proposed
framework has been developed using a variety of hy-
pothetical test cases. However, used in tandem with
real patient data and other clinical diagnostic tools
[47, 48], the developed algorithm may enable patient-
specific, leukemia-specific disease dynamic modeling for
actual patients with CLL. It also provides insight into
the trajectory of disease progression and presents CLL
cell migration and propensity towards proliferation as
avenues of future research.
5. CONCLUSIONS
This paper develops the first physiologically-relevant
mathematical model of CLL connecting the most af-
fected tissues. The mathematical novelty stems from the
integration of both temporal and spatial CLL aspects.
The delay differential equations incorporate the temporal
aspect of cell division. The model is practical in that
(1) measurable input parameters have been taken from
common clinical protocols, (2) from data which is read-
ily accessible in current standard clinical practice, (3) it
captures physiologically-relevant transitions from Binet
Stage A to C and, (4) it predicts outcomes which may
be clinically useful for expectant patient care if validated
using primary patient data. Using the model, we found
that CLL cell migration between disease centers and
the induction of CLL cells into proliferative phase are
critical parameters determining disease evolution and
should be evaluated in future research.
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TABLE 7: Symbol Definition
Symbol Value Units Description Source
Indices
CLL B-Cell Chronic Lymphocytic Leukemia Cells
t ∈ {in, fin} Time points t; in ≡ initial; fin ≡ final
d ∈ {LB, AV, UB} Data d: LB ≡ Lower Bound; AV ≡ Average; UB ≡ Upper Bound
h ∈ {BM2PB, PB2LN} Net flow h of CLL cells: BM2PB ≡ bone marrow → peripheral blood; PB2LN ≡
peripheral blood → lymph nodes and spleen
i ∈ {NC, BM, PB, LN, S} Cell types i; NC ≡ Normal lymphocyte in any tissue; BM ≡ CLL in bone marrow
(proliferating region); PB ≡ CLL in peripheral blood (non-proliferating region); LN
≡ CLL in lymph node (proliferating region); S ≡ CLL in spleen (proliferating
region, grouped with LN in our analysis); LC ≡ lymphocytes
z ∈ {SN, SA, SB, SC} Stage of the disease: SN ≡ Naïve Stage; SA ≡ Binet Stage A; SB ≡ Binet Stage B;
SC ≡ Binet Stage C
State
Variables
Pi cells Proliferating cells in compartments i ∈ {NC, BM, PB, LN}
Ni cells Non-proliferating cells in compartments i ∈ {NC,BM, PB, LN}
Assumed
Parameters
aBM 24.7± 9.7 % Percentage of lymphocytes in healthy bone marrow [38]
βNi, 0 3.35 1/day Maximum recruitment rate [23, 25]
dLN,NC [1, 2] cm Normal lymph node diameter [49]
dS,NC 5 cm Normal spleen diameter Table G.1†
lS,NC 11 cm Normal spleen length Table G.1†
ni 3 – Control shape of the Eq (D.7) feedback function [23, 25]
VLN,NC 0.52 cm3 Normal lymph node volume Eq (G.1)†
VS 215.86 cm3 Normal spleen volume (147.50 ± 81.46) [50]
VCLL 166×10−12 cm3 Volume of a CLL cell [51]
tin, z day Time when disease stage z starts
tfin, z day Time when disease stage z finishes
CNC,BM 50×109 cells Normal number of lymphocytes in bone marrow Table 2
BMmax 13.5× 1011 cells Maximum number of cells in bone marrow Appendix B†
%Ki-67i,AV % Average Ki-67 of CLL in tissues. Ki-67BM,AV = 2.48± 0.77%; [26]






dS,CLL [5, 10] cm Enlarged spleen diameter Table G.1†
lS,CLL [11, 28] cm Enlarged spleen length Table G.1†
dLN,CLL [≥ 1, 6] cm Enlarged lymph node diameter [7]
% Ki-67i % Percentage of Ki-67 in compartments ∀ i ∈ {NC, BM, PB, LN} Eq (4)
%BMlymph % Percentage of lymphocytes in bone marrow Eq (5)
VCLL, LN cm3 Volume of an enlarged lymph node Eq (G.2)†
NuLN, dLN, CLL Number of enlarged lymph nodes of diameter dLN,CLL Eq (G.5)
†
VCLL, S cm3 Volume of CLL cells in spleen Eq (G.7)†
Initial
Conditions
NBM, PBM cells %Ki-67BM and %BM in Eq 5
NPB, PPB cells %Ki-67PB and blood tests
NLN, PLN cells %Ki-67LN and CT scans
Calculated
Parameters
δi, z 1/day Cell death rate in quiescent phase ∀ i ∈ {NC, BM, PB, LN} [23, 25]
δBM ∈ [0.001, 0.080]; δPB ∈ [0.001, 0.020]; δLN ∈ [0.001, 0.020] [30, 32]
γi, z 1/day Rate of cell loss from proliferating phase ∀ i ∈ {NC, BM, PB, LN} [23, 25]
γBM ∈ [0.001, 1.000]; γPB ∈ [0.001, 1.000]; γLN ∈ [0.001, 1.000] [30, 32]
τi, z [0.625, 0.792] day Time spent in proliferative phase in compartments i ∈ {NC, BM, PB, LN} [29]
kN, h, z; kP, h, z 1/day Migration rate of (non-)proliferative (N/P) cells for net flows h Appendix D†
θi, 1, z; θi, 2, z cells Parameters of θi function Appendix D†
Variables
θi cells Control shape of the feedback function ∀ i ∈ {NC, BM, PB, LN} Eq (3)
βi 1/day Hill feedback function Eq (D.7)†
V∗CLL, LN cm
3 Volume of an enlarged lymph node based on lymphocytes Eq (G.3)†
(N+P)CLL, LN cells Number of CLL cells per lymph node Eq (G.4)†
NuLN, dLN, CLL Number of enlarged lymph nodes of diameter dLN,CLL Eq (G.5)
†
V∗CLL, S cm
3 Volume of CLL cells in spleen Eq (G.7)†
(N + P )CLL, S cells Total number of CLL cells in spleen Eq (G.8)†
cc Bone marrow carrying capacity Eq (6)
dS,CLL [5, 10] cm Enlarged spleen diameter Table G.1†
lS,CLL [11, 28] cm Enlarged spleen length Table G.1†
dLN,CLL [≥ 1, 6] cm Enlarged lymph node diameter [7]
% Ki-67i % Percentage of Ki-67 in compartments ∀ i ∈ {NC, BM, PB, LN} Eq (4)
%BMlymph % Percentage of lymphocytes in bone marrow Eq (5)
VCLL, LN cm3 Volume of an enlarged lymph node Eq (G.2)†
VCLL, S cm3 Volume of CLL cells in spleen Eq (G.7)†
Ni, τi, z cells Number of CLL cells in tissues at time t− τi at stage z Eq (1)
Ni(t− τi, z) cells Number of CLL cells in tissues at time t− τi at stage z Eq (1)
† Material in the Online Supplementary Material
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APPENDIX A
BASIC G0 CELL CYCLE MODEL
Fig. A.1: The G0 cell cycle model [23, 25]
We represent lymphocyte proliferation using the 2-
compartment delay differential equation (DDE) model
illustrated in Fig. A.1 [23, 25]. The non-proliferative
compartment N [cells] represents the resting (G0) phase
and the proliferative compartment P [cells] aggregates
the remaining cell cycle phases (G1, S, G2, M). Non-
proliferative cells migrate to the proliferative compart-
ment where they divide in fixed time τ (day); the time




=− δNC NNC − βNC(NNC) NNC





=− γNC PNC + βNC(NNC) NNC
− βNC(NτNC,NC) NτNC,NC e−γNC τNC
(A.2)
The feedback from non-proliferative to proliferative
compartment is given by β (1/day) with maximum entry
rate βN, 0 (1/day) and control shape n, θ (cells) of Eq
(D.7). The apoptotic rate in the non-proliferative and
proliferative compartments is δ (1/day) and γ (1/day),
respectively [23, 25].
APPENDIX B
PERCENTAGE OF LYMPHOCYTES IN BONE MARROW
AND BONE MARROW CARRYING CAPACITY
The mean lymphocyte percentage in healthy human
bone marrow biopsies is aBM = 25% (Range: 9− 37%)
[38]. From Table 2, the total number of lymphocytes
in bone marrow is CNC,BM = 50× 109. If healthy bone
marrow could be evacuated, the total number of analysed
cells would be roughly CNC,BM/aBM and we can use
Fig. C.1: CLL BM infiltration patterns [6, 28]; BM
infiltration pattern, %BMCLL, is typically nodular or
interstitial in Naïve stage or Binet Stage A & B, mixed
in Binet Stage B & C and diffuse in Binet Stage C
Eq 5 to calculate %BMlymph, the increased bone marrow
lymphocyte percentage due to CLL. Observe in Figure
F.2 that aBM is relatively unimportant in the model
The maximum fraction of CLL cells in BM is 90%.
Assuming a constant number (50× 109) of normal BM
lymphocytes [21, 22], we estimate a maximum of 13.5×
1011 lymphocytes in heavily-infiltrated BM:
%BMlymph =
CNC,BM +NBM + PBM
1
aBM
CNC,BM + PBM +NBM
⇔
90% =
50× 109 +NBM + PBM
1
25%50× 109 +NBM + PBM
⇔
NBM + PBM = 13.0× 1011
APPENDIX C
CALCULATING THE BONE MARROW INFILTRATION
PATTERN
Accumulating CLL cells may increase the proportion
and change the infiltration pattern of BM lymphocytes;
lymphocytes typically represent 24.7 ± 9.6% of white
blood cells (WBCs) on healthy human BM aspirates
but may be > 80% in later CLL stages [38]. Fig.
C.1 diagrams the four CLL BM infiltration patterns:
interstitial; nodular; mixed; diffuse [28]. In the inter-
stitial pattern, the lymphocyte percentage ranges 30 –
50% (light BM infiltration) [6, 28]; mature lymphocytes
replace hematopoietic tissue to some degree but BM
structure and fat cells are preserved. In the nodular
pattern, the lymphocyte percentage also ranges 30 –
50%, fat cells are preserved and there is no interstitial
infiltration [6, 28], but nodules of mature lymphocytes
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appear with diameter longer than the lymphoid follicles.
In mixed pattern, the percentage of lymphocytes ranges
50 – 80% (moderate BM infiltration) [6, 28] and there
is both interstitial and nodular infiltration. In diffuse
pattern, the percentage of lymphocytes is > 80% (heavy
BM infiltration) [6, 28] and there is massive replacement
of hematopoietic tissue by mature lymphocytes.
APPENDIX D
PARAMETER ESTIMATION
In a CLL disease stage z ∈ {SN, SA, SB, SC}, both
t = tin and t = tfin should require:
−δBM, z NBM, t, z − βBM (NBM, t, z) NBM, t, z cct, z
+2 βBM(NBM, t, z) NBM, t, z e
−γBM, z τBM, z cct, z
−kN, BM2PB, z NBM, t, z = NBM, fin, z −NBM, in, z
tfin, z − tin, z
(D.1)
−δPB, z NPB, t, z − βPB (NPB, t, z) NPB, t, z
+2 βPB(NPB, t, z) NPB, t, z e
−γPB, z τPB, z
+kN, BM2PB, z NBM, t, z − kN, PB2LN, z NPB, t, z
=
NPB, fin, z −NPB, in, z
tfin, z − tin, z
(D.2)
−δLN, z NLN, t, z − βLN (NLN, t, z) NLN, t, z
+2 βLN(NLN, t, z) NLN, t, z e
−γLN, z τLN, z
+kN, PB2LN, z NPB, t, z =
NLN, fin, z −NLN, in, z
tfin, z − tin, z
(D.3)
−γBM, z PBM, t, z + βBM (NBM, t, z) NBM, t, z cct, z
−βBM(NBM, t, z) NBM, t, z e−γBM, z τBM, z cct, z
−kP, BM2PB, z PBM, t, z = PBM, fin, z − PBM, in, z
tfin, z − tin, z
(D.4)
−γPB, z PPB, t, z + βPB (NPB, t, z) NPB, t, z
−βPB(NPB, t, z) NPB, t, z e−γPB, z τPB, z
+kP, BM2PB, z PBM, t, z − kP, PB2LN, z PPB, t
=
PPB, fin, z − PPB, in, z
tfin, z − tin, z
(D.5)
−γLN, z PLN, t, z + βLN (NLN, t, z) NLN, t, z
−βLN(NLN, t, z) NLN, t, z e−γLN, z τLN, z
+kP, PB2LN, z PPB, t, z =
PLN, fin, z − PLN, in, z
tfin, z − tin, z
(D.6)
where i ∈ {BM, PB, LN} and z ∈ {SN, SA, SB, SC}
βi(Ni, t, z) = βNi, 0/ (1 + (ui, t, z)
ni) (D.7)
ui, t, z = Ni, t, z/θi,t,z (D.8)
θi, 2, z = θi, tin, z (D.9)
θi, 1, z =
θi, tfin, z − θi, tin, z
tfin, z − tin, z (D.10)
θi = θi, 1, z (t− tin, z) + θi, 2, z. (D.11)
Furthermore, we assume:
(a) The constraints of ui, t, z are:
uLBBM = 2 ≤ uBM, t, z ≤ uUBBM = 20 (D.12)
uLBPB = u
UB
PB = 20 (D.13)
uLBLN = 2 ≤ uLN, t, z ≤ uPB, t, z (D.14)
If NLN, tin, z+PLN, tin, z ' 0 then uLN, tin, z = uPB, tin, z
(b) Apoptotic rates bounds from Table 7 [1/day]:
δLBBM = 0.001 ≤ δBM, z ≤ δUBBM = 0.080 (D.15)
δLBPB = 0.001 ≤ δPB, z ≤ δLBPB = 0.020 (D.16)
δLBLN = 0.001 ≤ δLN, z ≤ δUBLN = 0.020 (D.17)
γLBi = 0.001 ≤ γi, z ≤ γUBi = 1.000 (D.18)
(c) Apoptotic rates for proliferating cells may be high
when they lose contact with T cells [52].
γi, z ≥ δi, z (D.19)
Fig. D.1: Iterative procedure for disease stage z1; sub-
sequent stages are equivalent. Intermediate MATLAB
outputs (marked *) should match Table E.1 (no *)
(d) Migration rate lower and upper bounds are 0.001 and
1.000, respectively. We assume lower migration rates
for proliferating cells than non-proliferating cells in
bone marrow because of the niche:
kP,BM2PB, z ≤ kN,BM2PB, z (D.20)
(e) If CLL cells are accumulating in PB, use Eq (D.21),
otherwise use Eq (D.22):
NBM, fin, z ≥ kN, PB2LN, z
kN,BM2PB, z
NPB, fin, z (D.21)
NBM, fin, z ≤ kN, PB2LN, z
kN,BM2PB, z
NPB, fin, z (D.22)
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(f) Migration rates from PB to LN are related to the






kP, PB2LN, z ≤ kN, PB2LN, z Ki-67LN,AVKi-67PB,AV ; (D.23)
(g) Time [day] spent in proliferative phase [29]:
τLBi = 0.625 ≤ τi, z ≤ τUBi = 0.792 (D.24)
(h) Only in the parameter estimation:
cct, z = 1 (D.25)
Eqs (D.1) – (D.25), seeded with the initial and
final number of cells measured at different time
points (Tables 5 & E.1), are solved as a feasibility
problem in GAMS. Final conditions at t = tfin are
set by expected values depending on the disease
stage (see Tables 1 & C.1 and Appendix C). The
GAMS output is a set of parameter values τi, z1,
δi, z1, γi, z1, θi, 1, z1, θi, 2, z1, kN,BM2PB,z1, kP,BM2PB, z1,
kN, PB2LN, z1 and kP, PB2BM, z1 ∀ i ∈ {BM, PB, LN},
z1 ∈ {SN, SA, SB} satisfying the constraints.
We enter the output parameters from the GAMS fea-
sibility problem into the set of DDEs in MATLAB and
check that final conditions agree with expected values.
If the MATLAB output is not as expected, we vary the
parameters first in BM and then in LN:
(a) If the relative error of Ki-67, εKi-67k, tfin, z1 > 15%
for k ∈ {BM, LN}, we minimize εKi-67k, tfin, z1 by
sampling over the lower and upper bound of γk, z1;




(b) If the relative error of Nk, εNk, tfin, z1 > 20%, we
increase or decrease control parameter θk, 1, z1 for
insufficiency or hypersufficiency, respectively. We
increment θk, 1, z1 by increasing the highest non-zero
digit of the initial θk, 1, z1 by 1 until the flowsheet
in Fig. D.1 is satisfied:




For trajectories spanning two Binet stages, the final
values of the first stage are initial conditions for the
second disease stage (Table E.1) and, for the second
disease stage, only parameters varying within a disease
stage, e.g., the control function and migration rates) are
calculated by GAMS. Solving for the second disease
stage is similar except that we tighten the tolerance in
step (a) above to 10%. Recall here that our goal is finding
reasonable rather than optimal parameters; Appendix
H demonstrates the results using a multistart strategy
since there are multiple possible outputs of the GAMS
feasibility problem.
APPENDIX E
INITIAL AND FINAL EXPECTED CONDITIONS
Representing patient heterogeneity, Table 5 posits
symptoms of 5 hypothetical patients. For each tissue in
each disease stage, we estimate the fraction of prolifera-
tive cells using expected Ki-67 expression (Table 5). PB
lymphocyte counts are based on expected LDT values
(Table 1) and BM infiltration patterns are chosen with
respect to CLL disease progression (Table C.1).
This study focusses on cells migrating from BM to
PB and then from PB to LN and S; initial numbers of
enlarged LN in the 5 patients correspond to expected
disease stage. Final CLL cell count is based on expected
lymphadenopathy and splenomegaly in CLL. As in PB
and BM, the expected proliferative cell fraction in LN
and S is based on expected values of Ki-67 (Table 5).
APPENDIX F
GLOBAL SENSITIVITY ANALYSIS
RS-HDMR, like the Sobol global sensitivity analysis






















f(x) dxij − fi(xi)− fj(xj)− f0
. . .
and x = [x1, x2, . . . , xn] is the input of parameters
whose values change; dxi is the product dx1dx2 . . . dxn;
dxij is the same product without dxi and dxj . This de-
composition, also called analysis of variance (ANOVA),
creates unique, orthogonal terms and reveals both first-
and higher-order effects to model output via variance-















f2i, j(xi, xj) dxi dxj . . .
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TABLE E.1: Initial and final conditions in hypothetical patients P1 – P5 and initial steps in GAMS
Patient 1 (P1)
Naïve initial (0 day) Naïve final (1000 day) Binet A initial (1000 day) Binet A final (3190 day)
NBM (·108 cells) 380.000 380.010 380.010 667.000
NLN (·108 cells) 0.010 912.000 912.000 3662.000
NPB (·108 cells) 300.000 329.000 329.000 660.000
PBM (·108 cells) 10.500 13.500 13.500 19.000
PLN (·108 cells) 0.000 42.000 42.000 172.500
PPB (·108 cells) 0.900 1.500 1.500 2.380
What changed to 2nd stage only θs and migration rates change in GAMS
Patient 2 (P2)
Binet A initial (0 day) Binet A final (1800 day) Binet B initial (1800 day) Binet B final (2165 day)
NBM (·108 cells) 800.000 1108.000 1108.000 1815.000
NLN (·108 cells) 1300.000 2075.000 2075.000 2556.000
NPB (·108 cells) 400.000 661.000 661.000 1423.000
PBM (·108 cells) 15.900 33.110 33.110 60.000
PLN (·108 cells) 40.000 97.800 97.800 132.000
PPB (·108 cells) 0.810 2.380 2.380 5.140
What changed to 2nd stage all parameters change in GAMS except τs
Patient 3 (P3)
Binet A initial (0 day) Binet A final (365 day) Binet B initial (365 day) Binet B final (730 day)
NBM (·108 cells) 800.000 1108.000 1108.000 1750.000
NLN (·108 cells) 1300.000 2550.000 2550.000 3877.000
NPB (·108 cells) 400.000 862.000 862.000 1826.000
PBM (·108 cells) 15.900 33.110 33.110 58.000
PLN (·108 cells) 40.000 120.158 120.158 212.000
PPB (·108 cells) 0.810 3.113 3.113 6.591
What changed to 2nd stage only θs and migration rates change in GAMS
Patient 4 (P4)
Binet B initial (0 day) Binet B final (365 day) Binet C initial (365 day) Binet C final (730 day)
NBM (·108 cells) 1100.000 1933.000 1933.000 4934.000
NLN (·108 cells) 1300.000 15806.000 15806.000 38334.000
NPB (·108 cells) 4200.000 9140.000 9140.000 18332.000
PBM (·108 cells) 34.129 57.110 57.110 158.000
PLN (·108 cells) 26.000 744.158 744.158 2317.000
PPB (·108 cells) 8.410 33.114 33.114 59.591
What changed to 2nd stage only θs and migration rates change in GAMS
Patient 5 (P5)
Binet A initial (0 day) Binet A final (365 day) Binet C initial (365 day) Binet C final (730 day)
NBM (·108 cells) 390.000 390.410 390.410 7030.000
NLN (·108 cells) 1000.000 2455.150 2455.150 7832.000
NPB (·108 cells) 900.000 1029.000 1029.000 2666.000
PBM (·108 cells) 7.000 7.390 7.390 210.000
PLN (·108 cells) 47.110 115.500 115.500 545.000
PPB (·108 cells) 2.000 3.713 3.713 10.000
What changed to 2nd stage all parameters change in GAMS except τs
The sensitivity indices are given by:
Si1, ..., is =
Di1, ..., is
D
, 1 ≤ i1 < . . . < is ≤ n






Si, j + . . .+ S1, 2, ..., n = 1
The main effect of the input variable xi on the output
is calculated by the first order sensitivity index Si while
the effect of xi and xj on the output is given by the
second order sensitivity indices and so on. Fig. parameter
ranking is done for each of the model outputs.
Global sensitivity analysis of two compartments, like
that in Fig. A.1 with initial conditions N0 = 1809 · 108
cells, P0 = 54·108 cells and N/θ << 20 (proliferation),
shows that the most important parameters in the non-
proliferative population are θ1 > θ2 > γ > β0 > τ > δ
(Fig. F.1) and the most important parameters in the
proliferative population are γ > θ1 > τ > β0 >
θ2 > δ (Fig. F.1). θ1 increases both the non-proliferative
and proliferative populations but γ decreases the non-
proliferative population and increases the proliferative
population because it decreases the rate of cells which
pass through the proliferative phase.
Table F.1 contains parameters and their relevant ranges
for sensitivity analysis; we have previously analyzed a
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TABLE F.1: Ranges of parameters used in RS-HDMR analysis of CLL framework from Binet Stages A to C
Parameter (Units) Nominal Value Minimum Value Maximum Value Ref.
γBM (1/day) 0.565 0.091 0.823 Table 4
γLN (1/day) 0.706 0.530 0.866 Table 4
γPB (1/day) 0.001 0.001 0.003 Table 4
δBM (1/day) 0.001 0.001 0.037 Table 4
δLN (1/day) 0.001 0.001 0.020 Table 4
δPB (1/day) 0.001 0.001 0.003 Table 4
τBM (day) 0.792 0.625 0.792 [29]
τLN (day) 0.792 0.625 0.792 [29]
τPB (day) 0.792 0.625 0.792 [29]
θBM, 1 (·108 cells) 0.010 0.004 6.209 Table 4
θBM, 2 (·108 cells) 3 ≤ NBM, 0/θBM, 2 ≤ 5 Table 4
θLN, 1 (·108 cells) 0.279 0.154 19.297 Table 4
θLN, 2 (·108 cells) 3 ≤ NLN, 0/θLN, 2 ≤ 4.5 Table 4
θPB, 1 (·108 cells) 0.001 0.001 1.259 Table 4
θPB, 2 (·108 cells) NPB, 0/θPB, 2 ≥ 20 Table 4
kN,BM2PB (1/day) 0.003 0.001 0.035 Table 4
kP,BM2PB (1/day) 0.001 0.001 0.003 Table 4
kN, PB2LN (1/day) 0.003 0.001 0.005 Table 4
kP, PB2LN (1/day) 0.013 0.001 0.033 Table 4
nBM 3 2 4 [23, 43]
nLN 3 2 4 [23, 43]
nPB 3 2 4 [23, 43]
βNBM, 0 (1/day) 3.350 1.690 (-50%) 5.070 (+50%) [25]
βNLN, 0 (1/day) 3.350 1.690 (-50%) 5.070 (+50%) [25]
βNPB, 0 (1/day) 3.350 1.690 (-50%) 5.070 (+50%) [25]
aBM 0.25 0.09 0.37 [38]
BMmax (·108 cells) 13500 6750(-50%) 20250(+50%) Appendix B
CNC,BM(·108 cells) 500 250(-50%) 750(+50%) Table 2
NBM, 0 (·108 cells) 380.000 380.000 2000.000 Table 4
NLN, 0 (·108 cells) 1000.000 1000.000 15000.000 Table 4
NPB, 0 (·108 cells) 300.000 300.000 9000.000 Table 4
Fig. F.1: Global sensitivity analysis of a two compart-
mental model in which all the parameters change ±50%
except τ ∈ [0.625, 0.792] day for 2000 steps
subset of these parameters on a different CLL model
[18]. Table F.1 lists ranges for non-proliferative initial
conditions but not for proliferative initial conditions
because non-proliferative and proliferative tissue are
related with respect to Ki-67 measurements (Table 5).
In the analysis, the maximum order for approximation
of the first and second order component functions is 10
and 5, respectively. Ten iterations are used for both the
first and second order component functions.
APPENDIX G
CALCULATING THE NUMBER OF ENLARGED LYMPH
NODES AND PREDICTING THE SPLEEN PATTERN
TABLE G.1: Cases of splenomegaly and spleen size [54]
Severity Size (width × length)
Mild to Moderate ≥ 5× 11 cm
Marked ≥ 6× 16 cm
Extreme ≥ 8× 20 cm
The body has ≈ NuLN = 800 LN which are the
primary defense mechanism against infection [55]; each
LN typically has diameter d = 1 – 2 cm and is connected
to other LN via lymphatic vessels [49]. We approximate
LN as spheres and S as a cylinder. What causes the
change of the size of LN and S is the increased number
of migrated CLL cells whose shape can be assumed as
spheres with volume VCLL = 166 · 10−12 cm3 [51]. The
sequel explains how we estimate the number of enlarged
LN when either the S is normal or enlarged.
1) Size & number of enlarged LN with normal S:
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Fig. F.2: Average values of Si ± SD indices in each non-proliferative and proliferative output for hypothetical
patients P1 – P5
(a) Calculating LN volume: Each LN has diameter








= 0.52 cm3 (G.1)
(b) Counting CLL cells in enlarged LN: The volume










We assume that normal lymphocyte count is con-
stant, i.e., the tissue is not replaced, so the volume
of CLL cells in an enlarged LN is V ∗CLL, LN:
V ∗CLL, LN = VCLL, LN − VLN (G.3)
The number of CLL cells per LN ((N + P )CLL, LN)
are calculated by dividing the volume of CLL cells
(VCLL) in LN:
(N + P )CLL, LN = V
∗
CLL, LN/VCLL (G.4)
Calculating the number of enlarged LN with diam-
eter dLN,CLL:
NuLN, dLN, CLL =
NLN + PLN
(N + P )CLL, LN
(G.5)
2) Size & number of enlarged LN with enlarged S:
(a) Calculating the total volume of S: Normally, S
has diameter dS,NC ≈ 5 cm and length lS,NC ≈ 11
cm; splenomegaly severity is given in Table G.1.
Assuming S is a cylinder, the S volume (VS) is:
VS = pi (5 cm/2)
2
11 cm = 215.86 cm3 (G.6)
Eq (G.6) agrees with experiment, VS = 147.50 ±
81.46 cm3 [50]. We assume that the normal lympho-
cyte count and the membrane volume are constant.
(b) Calculating the volume of enlarged S and the
number of CLL cells. The dimensions of the
enlarged S are given by the physician. If the mea-
sured thickness of the enlarged S is dS,CLL and its
measured length is lS,CLL, the volume of CLL cells
in S (VCLL, S) is given by:
VCLL, S = pi (dS,CLL/2)
2
lS,CLL − VS (G.7)
The number of CLL cells are calculated (N +
P )CLL, S, by dividing the volume of CLL cells in
S with the volume of one CLL cell:
(N + P )CLL, S = VCLL, S/VCLL (G.8)
For cases with enlarged S, the number of enlarged
LN is calculated by subtracting the number of CLL
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cells in S from the total number of CLL cells and
repeating the steps for calculating NuLN, dLN, CLL .
APPENDIX H
INITIALIZATION
Because the Appendix D procedure begins with solv-
ing a feasibility problem, there are multiple starting
points for the algorithm. We cannot prove that the
algorithm will always converge to the same point, but
this section demonstrates our computational experience
that results of the Appendix D algorithm give answers
within 10% of one another. Tables H.1 & H.2 provide
our computational experience with respect to patients P1
and P2. After initialising the GAMS feasibility problem
50 times, we had 4 distinct P1 feasible points (Table H.1)
and 3 distinct P2 feasible points (Table H.2). Running
the distinct points through the Appendix D algorithm
changed some of the parameters (as illustrated with →
in the tables). See in Fig H.1 that, although the lines are
not identical, the trajectories are within 10%.
Fig. H.1: Disease trajectories of P1 and P2 after multi-
starting the Appendix D algorithm; observe that the
trajectories are similar
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TABLE H.1: Results of an initial multistart strategy: Patient 1
Case 1 Case 2 Case 3 Case 4
Initial Final Initial Final Initial Final Initial Final
Transitions Naïve A Naïve A Naïve A Naïve A
γBM 1/day 0.796 1.000 0.796 0.001 → 0.792 0.004 → 0.724 0.002 → 0.767 0.774 0.774
γLN 1/day 1.000 0.844 → 0.858 0.001 → 0.867 0.858 0.863 0.001 → 0.857 0.861 0.861
γPB 1/day 0.001 0.008 0.001 0.001 0.001 0.001 0.001 0.001
δBM 1/day 0.001 0.001 0.001 0.001 0.004 0.002 0.001 0.001
δLN 1/day 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
δPB 1/day 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
τBM day 0.792 0.792 0.792 0.792 0.792 0.792 0.792 0.792
τLN day 0.683 0.792 0.792 0.792 0.790 0.792 0.792 0.792
τPB day 0.792 0.792 0.792 0.625 0.792 0.792 0.792 0.792
θBM, 1 ·108 cells 0.008 0.031 0.008 0.012 → 0.052 0.052 0.058 0.008 0.029
θBM, 2 ·108 cells 92.233 107.835 92.233 37.11 47.986 41.691 91.987 100.082
θLN, 1 ·108 cells 0.279 0.368 0.059 → 0.219 0.368 0.265 0.438 0.265 0.372
θLN, 2 ·108 cells 0.001 264.655 0.001 265.039 0.001 77.053 0.001 265.039
θPB, 1 ·108 cells 0.001 0.008 0.001 0.008 0.001 0.008 0.001 0.008
θPB, 2 ·108 cells 15.000 16.450 15.000 16.450 15.000 16.450 15.000 16.450
kN,BM2PB 1/day 0.003 0.002 0.003 0.002 0.003 0.002 0.003 0.003
kP,BM2PB 1/day 0.003 0.001 0.003 0.001 0.001 0.001 0.003 0.001
kN, PB2LN 1/day 0.003 0.001 0.003 0.001 0.003 0.002 0.003 0.002
kP, PB2LN 1/day 0.025 0.001 0.033 0.007 0.008 0.007 0.033 0.007
TABLE H.2: Results of an initial multistart strategy: Patient 2
Case 1 Case 2 Case 3
Initial Final Initial Final Initial Final
Transitions A B A B A B
γBM 1/day 0.770 0.740 0.796 → 0.823 0.740 0.002 → 0.794 0.091
γLN 1/day 1.000 → 0.995 0.002 → 0.619 0.001 → 0.859 0.855 → 0.860 0.001 → 0.858 0.860
γPB 1/day 0.001 0.001 0.005 0.001 0.001 0.003
δBM 1/day 0.001 0.001 0.001 0.001 0.002 0.034
δLN 1/day 0.001 0.020 0.001 0.001 0.001 0.001
δPB 1/day 0.001 0.001 0.001 0.003 0.001 0.003
τBM day 0.792 0.792 0.792 0.792 0.792 0.792
τLN day 0.699 0.792 0.792 0.792 0.792 0.792
τPB day 0.625 0.625 0.625 0.625 0.792 0.625
θBM, 1 ·108 cells 0.057 0.526 0.057 0.522 0.118 0.481
θBM, 2 ·108 cells 173.123 274.733 173.649 274.325 80.337 258.275
θLN, 1 ·108 cells 0.162 -0.193 → 0.293 0.025 → 0.225 0.450 0.256 0.451
θLN, 2 ·108 cells 344.553 524.785 87.137 607.614 87.120 607.436
θPB, 1 ·108 cells 0.007 0.104 0.007 0.104 0.007 0.104
θPB, 2 ·108 cells 20.000 33.05 20.000 33.05 20.000 33.05
kN,BM2PB 1/day 0.003 0.004 0.001 0.004 0.001 0.004
kP,BM2PB 1/day 0.001 0.004 0.001 0.001 0.001 0.001
kN, PB2LN 1/day 0.005 0.003 0.001 0.001 0.001 0.001
kP, PB2LN 1/day 0.013 0.046 0.014 0.009 0.013 0.007
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